ANALYSIS: With an Obermatt 360° View of 98 (better than 98% compared with alternatives) for 2026, overall professional sentiment and financial characteristics for the stock Amylyx Pharmaceuticals are very positive. The 360° View is based on consolidating four consolidated indicators, with half below and half above average for Amylyx Pharmaceuticals. The consolidated Sentiment Rank has a good rank of 99, which means that professional investors are more optimistic about the stock than for 99% of alternative investment opportunities. It also rates well regarding its financing structure, with the consolidated Safety Rank at 77 or better than 77% of its peers when looking at the amount of its debt, its refinancing requirements, and its ability to service debt. But the stock is expensive and expects low growth. The consolidated Value Rank is only 31, meaning that the share price of Amylyx Pharmaceuticals is on the high side, compared with indicators such as revenues, profits, and invested capital. The company exhibits below-average growth momentum when looking at financial metrics such as revenue, profit, invested capital growth,and stock returns, with its Growth Rank at 40. ...read more